Navidea and its therapeutic subsidiary, Macrophage Therapeutic, are developing imaging and therapeutic products that target the CD206 (mannose receptor) found on activated macrophages. Because of extremely high binding (Kd’s of 10-11 to 10-13) of its proprietary delivery agents, Navidea has been able to effectively image both M1 and M2 macrophages in humans. Recently published data confirms M1 targeting, using our FDA approved delivery agent, based on clear imaging of emerging atherosclerosis in the aortic arch. Similar results have been generated in M1 mediated RA. Data has also been generated in Kaposi Sacroma patients evidencing M2 mediated disease.